Loading stock data…
TENX
$10.59-0.14 (-1.30%)
Market OpenUpdated 3:02 PM EDT
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tenax Therapeutics, Inc. in the Healthcare sector is trading at $10.59. Wall Street consensus targets $29.71 (7 analysts), implying a +180.6% move over the next 12 months. The stock is currently 42% below its 52-week high of $18.38, remaining 2.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +180.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.57M↓ | -$16.45M↑ | -$16.81M↓ | -$11.79M↓ | -$11.34M |
| Net Income | -$15.72M↓ | -$15.54M↑ | -$15.80M↓ | -$10.85M↓ | -$10.41M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-50.49%
Volume
Today's trading volume
292,612
Recent News
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. By way of example, Tenax Therapeutics...
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
Tenax Therapeutics: Q4 Earnings Snapshot
The Chapel Hill, North Carolina-based company said it had a loss of 38 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.26 per share.
Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference
Executives from Tenax Therapeutics (NASDAQ:TENX) outlined progress on the company’s Phase III development program for levosimendan in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) during a fireside chat at Guggenheim’s Emerging Outlook Biotech Confe
Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick
Tenax Therapeutics Inc (NASDAQ:TENX) is one of the best performing micro cap stocks in 2025. On December 17, Guggenheim raised its price target on Tenax Therapeutics Inc (NASDAQ:TENX) to $25 from $14 and maintained a Buy rating. The firm stated that its decision to nearly double the price target for Tenax relies on a specific […]